Why Shares Of Women's Health-Focused Biopharma Evofem Are Rallying

Evofem Biosciences Inc EVFM shares gap-opened higher Tuesday morning after a binary event panned out in the company's favor. 

FDA Greenlights Evofem's Contraceptive Gel

The San Diego, California-based biopharma, which focuses on therapies to address unmet needs in women's sexual and reproductive health, said late Friday the FDA approved Phexxi vaginal gel for the prevention of pregnancy as an on-demand method of contraception.

Phexxi is a vaginal pH regulator contraceptive designed to maintain vaginal pH within the normal range of 3.5 to 4.5 — an acidic environment that is inhospitable to sperm.

What It Means For Evofem

The company faced an earlier FDA rejection in April 2016. A resubmission was made in November 2019.

Phexxi presents a non-hormonal option to woman. Hormonal contraceptive treatments come with several side effects.

"Many of my patients have cycled through numerous contraceptive options and still have not found the right fit for their sexual and reproductive needs. Phexxi offers women freedom from hormones and control over how they choose to prevent pregnancy. I look forward to offering this new on-demand option to my patients," Michael Thomas, chair of the Department of Obstetrics and Gynecology at the University of Cincinnati College of Medicine, said in a statement. 

Oppenheimer projects 2024 U.S. net Phexxi sales of $350 million in contraception.

What's Next For Evofem

Evofem said it expects to launch Phexxi in early September alongside the Phexxi Concierge Experience, a comprehensive patient and health care provider telemedicine support system.

"Through this offering, women would be able to secure a prescription, determine their insurance coverage and/or out-of-pocket costs, receive counseling support and refill reminders, and fill their prescription through their local neighborhood pharmacy or an online pharmacy that is expected to deliver Phexxi right to their door," the company said.

The company said it is also working to get Affordable Care Act coverage for Phexxi.

EVFM Price Action

The stock was rallying by 18.22% to $5.90 at the time of publication Tuesday. 

Related Links:

The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Generic Threat To Amarin's Vascepa Overrides Positive Sentiment On Coronavirus Announcement

Posted In: OppenheimerPhexxiwomen's healthBiotechNewsFDAMoversTrading Ideas

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.